PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Genome British Columbia

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Genome BC, Chile and Norway Enter Next Phase in Sequencing the Critical Atlantic Salmon Genome - Access to a well-annotated salmon genome that will directly benefit the world’s fisheries and aquaculture industries is one step closer to reality
Genome BC, Chile and Norway Enter Next Phase in Sequencing the Critical Atlantic Salmon Genome

 

NewswireToday - /newswire/ - Vancouver, British Columbia, Canada, 2010/11/18 - Access to a well-annotated salmon genome that will directly benefit the world’s fisheries and aquaculture industries is one step closer to reality.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Access to a well-annotated salmon genome that will directly benefit the world’s fisheries and aquaculture industries is one step closer to reality as the International Cooperation to Sequence the Atlantic Salmon Genome (the Cooperation) is issuing a Request for Proposals (RFP) for Phase 2 of this multi-million dollar project.

Genome BC has partnered with the Chilean Economic Development Agency, InnovaChile, Norwegian Research Council, Norwegian Fishery and Aquaculture Industry Research Fund to form the Cooperation for this multi-phased project.

The project’s goal is to produce a genome sequence that identifies and maps the genes in the Atlantic salmon genome. This genome will then act as a reference/guide sequence for the genomes of other salmonids such as Pacific salmon, rainbow trout and more distantly related fish such as smelt and pike.

Unlike the human and mouse genome sequencing projects, the Atlantic salmon genome sequence will not be considered a “finished” sequence. The quality of the Atlantic salmon sequence will be critical as it must be sufficient to support detailed analyses, such as comparisons of duplicated regions within the genome and comparative genomics involving other fish species. Some of its applications will be the population management of wild fish stocks, food security and traceability, conservation of populations at risk and broodstock selection for commercially important traits.

The main objective of Phase 2 is the completion of the sequencing component, and will primarily be conducted using next generation sequencing technologies. The RFP is targeting large-scale sequencing centres or a consortium of academic and/or commercial centres that are believed to have the expertise and capacity to participate in a project of this scale. The successful centre(s) will work collaboratively with the Cooperation to interpret and annotate the data. The RFP is being disseminated internationally.

Phase 1 of the project was awarded to Beckman Coulter Genomics to produce a genome with 4X coverage from Sanger sequencing using paired-end, plasmid, fosmid and BACs. It is expected that this phase will be completed by January, 2011.

The deadline to submit proposals to the Cooperation is no later than January 14, 2011.

All inquiries regarding the Cooperation, including the submission of proposals, can be directed in writing to the RFP Contact:
Dr. Steinar Bergseth
Chair, International Steering Committee, ICSASG
c/o The Office of the Chief Scientific Officer, Genome BC
E: mhasham[.]genomebc.ca / P: 604-675-1020

About Genome British Columbia

Founded in 2000, Genome BC (genomebc.ca) works collaboratively with government, universities and industry as the catalyst for a genomics-driven life sciences cluster with significant social and economic benefits for the Province and Canada. The organization's research portfolio, over $450 million since inception, includes 96 projects and technology platforms focused on areas of strategic importance to British Columbia such as human health, forestry, fisheries, bioenergy, mining, agriculture, and the environment. In addition, a critical element of responsible genomics research is to provide a forum through which accompanying environmental, ethical, economic, legal and social issues can be explored so that the context for scientific research remains focussed and relevant to society.
Genome BC programs are funded by the Provincial Government of British Columbia, Government of Canada through Genome Canada and Western Economic Diversification Canada, and other public and private partners.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Genome British Columbia

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Genome BC, Chile and Norway Enter Next Phase in Sequencing the Critical Atlantic Salmon Genome

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sally Greenwood - GenomeBC.ca 
604-637-4373 sgreenwood[.]genomebc.ca
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Genome British Columbia securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Genome British Columbia / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)